Enhanced Ocular Delivery of Cell Permeant Therapeutics for Retinal Edema Treatment

A novel system and method for treating retinal edema through targeted delivery of cell-permeant therapeutic conjugates, improving efficacy and safety.

The original patent disclosed compositions and methods for inhibiting diabeteic retinopathy and retinal vein occlusion using XIAP-BIR3 conjugates. However, these conjugates may have limited retinal targeting and retention, leading to reduced efficacy. The new inventive concept addresses these limitations by incorporating retinal targeting moieties, sustained release formulations, and mucoadhesive polymers to enhance retinal delivery and retention of the conjugates.

The new inventive concept comprises a system and method for treating retinal edema using cell-permeant therapeutic conjugates. These conjugates consist of a caspase-9 inhibitor, a cell-penetrating peptide, and a retinal targeting moiety. The conjugates are administered to the eye through an eye drop, which is formulated with a mucoadhesive polymer to enhance retention on the ocular surface. The retinal targeting moiety selectively binds to retinal cells, ensuring targeted delivery of the conjugate. In some embodiments, the caspase-9 inhibitor is a small molecule inhibitor administered in a sustained release formulation to provide prolonged inhibition of caspase-9 activity in the retina. The inventive concept also encompasses a composition for treating retinal edema, wherein the conjugate is formulated in a nanoparticle delivery system targeted to retinal cells using a retinal cell-specific ligand.

The new inventive concept introduces several novel features, including the use of retinal targeting moieties, sustained release formulations, and mucoadhesive polymers. These features provide a significant improvement over the original patent by enhancing retinal delivery and retention of the conjugates, leading to improved efficacy and safety.

Alternative embodiments of the inventive concept may include varying the type of caspase-9 inhibitor, cell-penetrating peptide, or retinal targeting moiety. Additionally, different nanoparticle delivery systems or mucoadhesive polymers could be used. The inventive concept could also be adapted for treating other ocular diseases, such as age-related macular degeneration or glaucoma.

The enhanced ocular delivery system and method for treating retinal edema have significant commercial potential in the ophthalmic industry. The market for retinal edema treatments is growing, driven by the increasing prevalence of diabetic retinopathy and retinal vein occlusion. The inventive concept offers a competitive advantage over existing treatments by providing improved efficacy and safety.